189 related articles for article (PubMed ID: 33416094)
1. FGD5‑AS1 promotes cisplatin resistance of human lung adenocarcinoma cell via the miR‑142‑5p/PD‑L1 axis.
Zhu F; Niu R; Shao X; Shao X
Int J Mol Med; 2021 Feb; 47(2):523-532. PubMed ID: 33416094
[TBL] [Abstract][Full Text] [Related]
2. CircPVT1 contributes to chemotherapy resistance of lung adenocarcinoma through miR-145-5p/ABCC1 axis.
Zheng F; Xu R
Biomed Pharmacother; 2020 Apr; 124():109828. PubMed ID: 31986409
[TBL] [Abstract][Full Text] [Related]
3. PRDM14 mediates chemosensitivity and glycolysis in drug‑resistant A549/cisplatin cells and their progenitor A549 human lung adenocarcinoma cells.
He S; Ma X; Zheng N; Wang G; Wang M; Xia W; Yu D
Mol Med Rep; 2021 Feb; 23(2):. PubMed ID: 33355367
[TBL] [Abstract][Full Text] [Related]
4. lncRNA RP11-838N2.3 Promoted Cisplatin Resistance in Lung Adenocarcinoma.
Chen J; Jiang F; Hu L; Zhang F; Wang J; Huang K; Wang Y
Biomed Res Int; 2020; 2020():2806042. PubMed ID: 32626737
[TBL] [Abstract][Full Text] [Related]
5. SLCO4A1-AS1 promotes cell growth and induces resistance in lung adenocarcinoma by modulating miR-4701-5p/NFE2L1 axis to activate WNT pathway.
Wei Y; Wei L; Li J; Ma Z; Zhang Q; Han Z; Li S
Cancer Med; 2020 Oct; 9(19):7205-7217. PubMed ID: 32762035
[TBL] [Abstract][Full Text] [Related]
6. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of lncRNA ANRIL inhibits the development of cisplatin resistance by upregulating miR‑98 in lung cancer cells.
Wang X; Zhang G; Cheng Z; Dai L; Jia L; Jing X; Wang H; Zhang R; Liu M; Jiang T; Yang Y; Yang M
Oncol Rep; 2020 Sep; 44(3):1025-1036. PubMed ID: 32705261
[TBL] [Abstract][Full Text] [Related]
8. Elevation of FGD5-AS1 contributes to cell progression by improving cisplatin resistance against non-small cell lung cancer cells through regulating miR-140-5p/WEE1 axis.
Fu J; Cai H; Wu Y; Fang S; Wang D
Gene; 2020 Sep; 755():144886. PubMed ID: 32534055
[TBL] [Abstract][Full Text] [Related]
9. Analysis of lncRNA UCA1-related downstream pathways and molecules of cisplatin resistance in lung adenocarcinoma.
Zhou H; Shen Q; Fu J; Jiang F; Wang L; Wang Y
J Clin Lab Anal; 2020 Aug; 34(8):e23312. PubMed ID: 32249461
[TBL] [Abstract][Full Text] [Related]
10. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
11. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
Huang Q; Xing S; Peng A; Yu Z
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
[TBL] [Abstract][Full Text] [Related]
12. LncRNA RP3-326I13.1 promotes cisplatin resistance in lung adenocarcinoma by binding to HSP90B and upregulating MMP13.
Zhou H; Huang X; Shi W; Xu S; Chen J; Huang K; Wang Y
Cell Cycle; 2022 Jul; 21(13):1391-1405. PubMed ID: 35298351
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of circ‑PVT1 inhibits the progression of lung adenocarcinoma and enhances the sensitivity to cisplatin via the miR‑429/FOXK1 signaling axis.
Cao L; Zhou X; Ding X; Gao D
Mol Med Rep; 2021 Oct; 24(4):. PubMed ID: 34328193
[TBL] [Abstract][Full Text] [Related]
14. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
Wang L; Shang X; Feng Q
Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
[TBL] [Abstract][Full Text] [Related]
15. LncRNA XIST promotes human lung adenocarcinoma cells to cisplatin resistance via let-7i/BAG-1 axis.
Sun J; Pan LM; Chen LB; Wang Y
Cell Cycle; 2017; 16(21):2100-2107. PubMed ID: 28961027
[TBL] [Abstract][Full Text] [Related]
16. The Long Noncoding RNA MEG3 Contributes to Cisplatin Resistance of Human Lung Adenocarcinoma.
Liu J; Wan L; Lu K; Sun M; Pan X; Zhang P; Lu B; Liu G; Wang Z
PLoS One; 2015; 10(5):e0114586. PubMed ID: 25992654
[TBL] [Abstract][Full Text] [Related]
17. CEACAM6 promotes cisplatin resistance in lung adenocarcinoma and is regulated by microRNA-146a and microRNA-26a.
Du H; Li Y; Sun R; Yuan Y; Sun S; Zhang Y
Thorac Cancer; 2020 Sep; 11(9):2473-2482. PubMed ID: 32648688
[TBL] [Abstract][Full Text] [Related]
18. The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression.
Liu Z; Sun M; Lu K; Liu J; Zhang M; Wu W; De W; Wang Z; Wang R
PLoS One; 2013; 8(10):e77293. PubMed ID: 24155936
[TBL] [Abstract][Full Text] [Related]
19. Deregulation of the miR-222-ABCG2 regulatory module in tongue squamous cell carcinoma contributes to chemoresistance and enhanced migratory/invasive potential.
Zhao L; Ren Y; Tang H; Wang W; He Q; Sun J; Zhou X; Wang A
Oncotarget; 2015 Dec; 6(42):44538-50. PubMed ID: 26517090
[TBL] [Abstract][Full Text] [Related]
20. An inverse interaction between
Zhang Y; Yuan Y; Li Y; Zhang P; Chen P; Sun S
Epigenetics; 2019 Oct; 14(10):949-960. PubMed ID: 31144606
[No Abstract] [Full Text] [Related]
[Next] [New Search]